The GSK Nuvalent acquisition is now officially complete. GSK plc (LSE/NYSE: GSK) confirmed on 15 July 2026 that it has finalized its purchase of Nuvalent, Inc., a Boston-based clinical-stage biopharmaceutical company focused on precisely targeted oncology therapies. The announcement was issued from London for media and investor audiences.
With the GSK Nuvalent acquisition finalized, GSK gains three lung cancer assets that immediately strengthen its oncology development pipeline. The deal brings two late-stage investigational therapies, zidesamtinib and neladalkib, along with an earlier-stage candidate, into GSK’s portfolio at a time when the company is actively building its presence in solid-tumor oncology.
GSK structured the transaction as a tender offer, acquiring all outstanding shares of Nuvalent (NASDAQ: NUVL). The deal was first announced on 9 June 2026, when GSK entered into a definitive agreement to acquire the company, and completion follows just over a month later.
This GSK Nuvalent acquisition news arrives as pharmaceutical companies continue to pursue bolt-on acquisitions of clinical-stage biotechs with validated, late-stage oncology assets, a strategy GSK’s leadership has pointed to directly in its own public statements.
Financial Details of the GSK Nuvalent Acquisition
Under the terms of the agreement, GSK completed a tender offer for all of Nuvalent’s outstanding shares. The aggregate equity value of the transaction is approximately $10.6 billion (£8.0 billion). Once cash acquired through the deal is netted out, GSK’s aggregate investment comes to approximately $9.4 billion (£7.1 billion).
Zidesamtinib (NVL-520) and Neladalkib (NVL-655)
Both zidesamtinib and neladalkib are considered potential best-in-class assets based on their clinical data profile to date. Each has been granted FDA Breakthrough Therapy Designation and Orphan Drug Designation, and both currently sit under active FDA review, with target decision dates expected later this year. If approved, GSK expects both therapies to launch in 2026, with the company citing multi-blockbuster commercial potential for the pair.
NVL-330: The Earlier-Stage Addition
Beyond the two lead assets, the GSK Nuvalent acquisition also brings in NVL-330, a candidate in Phase I development targeting HER2-altered non-small cell lung cancer. It represents the earliest-stage asset transferred in the transaction and extends GSK’s targeted lung cancer research beyond ROS1 and ALK alterations into HER2-driven disease.
